Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions
Current treatments for advanced hepatocellular carcinoma (HCC) have limited success in improving patients’ quality of life and prolonging life expectancy. The clinical need for more efficient and safe therapies has contributed to the exploration of emerging strategies. Recently, there has been incre...
Main Authors: | Xinguo Li, Xiaonan Sun, Bingyuan Wang, Yiling Li, Jing Tong |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-01-01
|
Series: | Asian Journal of Pharmaceutical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1818087622001209 |
Similar Items
-
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
by: M. Moehler, et al.
Published: (2019-08-01) -
Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy
by: Xianwang Wang, et al.
Published: (2023-07-01) -
Targeting Autophagy for Oncolytic Immunotherapy
by: Lulu Hu, et al.
Published: (2017-01-01) -
An Engineered Influenza a Virus Expressing the Co-Stimulator OX40L as an Oncolytic Agent Against Hepatocellular Carcinoma
by: Yang H, et al.
Published: (2024-01-01) -
Oncolytic Viruses in the Era of Omics, Computational Technologies, and Modeling: Thesis, Antithesis, and Synthesis
by: Laura Menotti, et al.
Published: (2023-12-01)